Copyright Reports & Markets. All rights reserved.

Global Acellular Pertussis-based Hexavalent Combination Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Prefilled
    • 1.3.3 Vial
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Public
    • 1.4.3 Private
  • 1.5 Global Acellular Pertussis-based Hexavalent Combination Vaccine Market Size & Forecast
    • 1.5.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Acellular Pertussis-based Hexavalent Combination Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 GSK
    • 2.1.1 GSK Details
    • 2.1.2 GSK Major Business
    • 2.1.3 GSK Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
    • 2.1.4 GSK Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 GSK Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
    • 2.2.4 Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 MSP Vaccine Company
    • 2.3.1 MSP Vaccine Company Details
    • 2.3.2 MSP Vaccine Company Major Business
    • 2.3.3 MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
    • 2.3.4 MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 MSP Vaccine Company Recent Developments/Updates

3 Competitive Environment: Acellular Pertussis-based Hexavalent Combination Vaccine by Manufacturer

  • 3.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Acellular Pertussis-based Hexavalent Combination Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Acellular Pertussis-based Hexavalent Combination Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturer Market Share in 2025
  • 3.5 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Region Footprint
    • 3.5.2 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Type Footprint
    • 3.5.3 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Market Size by Region
    • 4.1.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value (2021-2032)
  • 4.5 South America Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Acellular Pertussis-based Hexavalent Combination Vaccine Market Size by Country
    • 7.3.1 North America Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Market Size by Country
    • 8.3.1 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Acellular Pertussis-based Hexavalent Combination Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Acellular Pertussis-based Hexavalent Combination Vaccine Market Size by Country
    • 10.3.1 South America Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Acellular Pertussis-based Hexavalent Combination Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Acellular Pertussis-based Hexavalent Combination Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Acellular Pertussis-based Hexavalent Combination Vaccine Market Drivers
  • 12.2 Acellular Pertussis-based Hexavalent Combination Vaccine Market Restraints
  • 12.3 Acellular Pertussis-based Hexavalent Combination Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Acellular Pertussis-based Hexavalent Combination Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Acellular Pertussis-based Hexavalent Combination Vaccine
  • 13.3 Acellular Pertussis-based Hexavalent Combination Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Acellular Pertussis-based Hexavalent Combination Vaccine Typical Distributors
  • 14.3 Acellular Pertussis-based Hexavalent Combination Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Acellular Pertussis-based Hexavalent Combination Vaccine market size was valued at US$ 2419 million in 2025 and is forecast to a readjusted size of US$ 3518 million by 2032 with a CAGR of 5.5% during review period.
    An acellular pertussis-based hexavalent combination vaccine is a multivalent pediatric vaccine designed primarily for the primary immunization and, depending on national recommendations and product authorization, booster immunization of infants and young children. It is commonly designated as DTaP-IPV-HepB-Hib and combines diphtheria toxoid, tetanus toxoid, purified acellular pertussis antigens, inactivated poliovirus antigens, recombinant hepatitis B surface antigen, and a conjugated Haemophilus influenzae type b antigen. It therefore provides protection against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Hib. Compared with schedules using several monovalent or lower-valency vaccines, a hexavalent vaccine can reduce the number of injections, clinic visits and administration procedures, improving the convenience and operational efficiency of pediatric immunization. It is a technologically complex biological product rather than a simple antigen mixture, requiring multiple fermentation, cell-culture, recombinant-expression, purification, detoxification, conjugation, adsorption and formulation platforms, together with rigorous control of antigen compatibility, potency and manufacturing consistency.In 2025, global Acellular Pertussis-based Hexavalent Combination Vaccine production reached approximately 29 million units.The average gross profit margin of this product is 85%.
    The principal market opportunity is the continuing transition of pediatric immunization programs from fragmented, injection-intensive schedules toward simplified combination-vaccine schedules. Hexavalent products can preserve broad disease protection while reducing injections, appointment requirements and vaccine-handling procedures, potentially lowering the risk of delayed, missed or incomplete vaccination. The renewed circulation of pertussis in a number of regions has also reinforced the importance of timely completion of infant pertussis immunization. In established markets, demand is supported by the continued optimization of national childhood vaccination schedules and replacement of older combination products. In emerging economies, a larger long-term opportunity may arise as immunization systems move from pentavalent vaccines combined with separately administered hepatitis B or inactivated polio vaccines toward integrated hexavalent formulations. These trends favor companies with established antigen platforms, internationally compliant manufacturing capacity, dependable supply and experience in multinational registration and public-sector procurement.
    The principal barriers arise from scientific, manufacturing and regulatory complexity rather than an absence of medical need. Six antigen components must deliver appropriate immune responses and acceptable safety profiles within a common formulation or vaccination system, while avoiding clinically meaningful interference between components. Variability in one antigen, an interruption in a critical raw material or a delay in batch release can affect the availability of the entire vaccine. Manufacturers must also conduct extensive clinical evaluations covering primary schedules, booster use, interchangeability and co-administration with other pediatric vaccines, followed by continuous pharmacovigilance. Commercialization is further complicated by differences in national immunization schedules, tendering systems, reimbursement policies, local supply requirements and price negotiations. Waning pertussis immunity, changes in birth cohorts, vaccine hesitancy and fluctuations in government immunization budgets may also influence demand. Established products benefit from extensive clinical experience and physician confidence, creating a substantial time and credibility barrier for new entrants.
    Downstream purchasing criteria are expanding beyond disease coverage to include schedule efficiency, completion rates, supply reliability and value across the entire vaccination pathway. National immunization programs and public procurement agencies increasingly evaluate whether a vaccine can simplify delivery, reduce operational complexity at primary-care facilities and maintain dependable long-term supply. Private hospitals, pediatric clinics and self-pay vaccination markets place greater emphasis on fewer injections, convenient presentations, established safety records and parental acceptance. Digital immunization registries, appointment reminders and integrated child-health management systems are also improving the visibility of missed doses and supporting more standardized vaccination pathways, which strengthens the clinical value of combination vaccines. Future market expansion is therefore expected to be driven primarily by structural substitution for fragmented vaccination schedules rather than birth-cohort growth alone. Products capable of supporting both primary and booster strategies, adapting to different national schedules and demonstrating consistent real-world safety performance will be better positioned in downstream markets.
    This report is a detailed and comprehensive analysis for global Acellular Pertussis-based Hexavalent Combination Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Acellular Pertussis-based Hexavalent Combination Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Acellular Pertussis-based Hexavalent Combination Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Acellular Pertussis-based Hexavalent Combination Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Acellular Pertussis-based Hexavalent Combination Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Acellular Pertussis-based Hexavalent Combination Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Acellular Pertussis-based Hexavalent Combination Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, MSP Vaccine Company, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Acellular Pertussis-based Hexavalent Combination Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Prefilled
    Vial
    Market segment by Application
    Public
    Private
    Major players covered
    GSK
    Sanofi
    MSP Vaccine Company
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Acellular Pertussis-based Hexavalent Combination Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Acellular Pertussis-based Hexavalent Combination Vaccine, with price, sales quantity, revenue, and global market share of Acellular Pertussis-based Hexavalent Combination Vaccine from 2021 to 2026.
    Chapter 3, the Acellular Pertussis-based Hexavalent Combination Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Acellular Pertussis-based Hexavalent Combination Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Acellular Pertussis-based Hexavalent Combination Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Acellular Pertussis-based Hexavalent Combination Vaccine.
    Chapter 14 and 15, to describe Acellular Pertussis-based Hexavalent Combination Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now